Pfizer's Sasanlimab Combo Improves EFS In BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
27/4 09:56
(RTTNews) - Pfizer Inc. (PFE) announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance i...